News | Heart Valve Technology | September 14, 2015

Valtech's Cardioband Receives CE Mark Approval for Mitral Valve Repair

Device offers sutureless, transfemoral, transseptal delivery system for real-time adjustment

Valtech Cardio, Cardioband, CE Mark approval, mitral valve repair

Cardioband image courtesy of Valtech Cardio Ltd.

September 14, 2015 — Startup cardiovascular device manufacturer Valtech Cardio Ltd. announced it has received CE Marking for its Cardioband mitral reconstruction system (Cardioband), a proprietary, implantable mitral reconstruction device with a transfemoral, transseptal delivery system for mitral valve repair.

The designation, received from Dekra, Valtech's notified body in the European Union, was based on the results of a multicenter feasibility trial that demonstrated the safety and effectiveness of Cardioband in mitral valve repair and will allow Valtech to market and sell the device in the European Union. Results of the study demonstrated that Cardioband is a highly effective first-line treatment option for reducing mitral regurgitation (MR) and improving quality of life scores.

Valtech will officially unveil the Cardioband at the upcoming PCR London Valves meeting, Sept. 20-22, in Berlin.

MR is a condition in which the mitral valve leaflets fail to close properly, allowing backflow of blood from the left ventricle into the left atrium during systole. Left untreated, severe MR can eventually lead to a meaningful deterioration in cardiac function and, eventually, death. Approximately 4.2 million patients in the United States alone are affected by mitral valve disease, which represents a several-billion-dollar global market opportunity.

The Cardioband mitral reconstruction system enables surgical-like repair of the mitral valve annulus via a transfemoral, transseptal delivery system, allowing for real-time adjustment on a beating heart. The transcatheter, supra-annular approach does not interfere with the mitral valve leaflets or chordae, and does not preclude subsequent treatment options if they become necessary.

In a multicenter feasibility trial including more than 50 patients, Cardioband was shown to significantly reduce annular size, with significant improvement in MR. After six months of follow-up, 82 percent of patients (n = 22) were categorized in New York Heart Association (NYHA) Class I-II, with significant improvement of quality of life (Minnesota Living With Heart Failure Questionnaire) score of 38 to 18 [p<0.05]; and had six-minute walk test score of 250 to 322 [p<0.05]). At 12 months' follow-up, 94 percent of patients (n = 17) had sustained MR less than or equal to 2+.

"The future of functional mitral regurgitation  treatment lies in the repair-and-replace paradigm," commented Francesco Maisano, M.D., first user of the Cardioband procedure and chairman and professor of cardiovascular surgery at The University Hospital of Zurich. "MR repair with Cardioband can be the first-line therapy for severe MR patients. Additionally, early-stage repair can support ventricular reverse remodeling while keeping the options open for the patient, supporting the technology's use at earlier stages."

The Cardioband System combines a reconstruction implant, similar to the surgical annuloplasty devices, with a transfemoral, transseptal delivery system. Connection of the implant to the mitral annulus is sutureless, using specially designed anchors. Reshaping of the mitral annulus to eliminate MR is done under physiological conditions and echocardiographic guidance for optimal results.

For more information:

Related Content

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation. Abbott Mitraclip device.

A MitraClip device being deployed to clasp together the leaflets of the mitral valve. This mimics a surgical suture repair to create a double orifice valve with better leaflet coaptation to prevent mitral regurgitation.

News | Structural Heart | May 11, 2018
May 11, 2018 — The post-approval study evaluating the safety and efficacy of MitraClip in a real-world, commercial se
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart | April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
Overlay Init